Financing to be conducted by UBS, BMO Capital, Wells Fargo and Needham
By Devika Patel
Knoxville, Tenn., April 7 – Aeglea BioTherapeutics, Inc. said it priced its $50 million initial public sale of stock with a $7.5 million greenshoe. The deal was announced June 16.
The company will sell 5 million common shares at $10.00 apiece.
UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities are the bookrunning managers.
Settlement is expected April 12.
Proceeds will be used for product development and advancement, research and development and working capital.
The biopharmaceutical company is based in Austin, Texas. The company intends to list its common stock on the Nasdaq under the symbol “AGLE.”
Issuer: | Aeglea BioTherapeutics, Inc.
|
Issue: | Common stock
|
Amount: | $50 million
|
Greenshoe: | $7.5 million, 750,000 shares
|
Shares: | 5 million
|
Price: | $10.00
|
Warrants: | No
|
Bookrunners: | UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities
|
Co-manager: | Needham & Co.
|
Announcement date: | June 16
|
Pricing date: | April 7
|
Settlement date: | April 12
|
Stock exchange: | Nasdaq: AGLE
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.